Visalytics
Visalytics
approved EB-2 (NIW)

Hospitalist

Immunotherapies · Turkey · 2025-04-17

Processing Time
15 days
Decision Date
2025-04-17
Location
New York
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to enhance the understanding of chronic diseases, including cancer, diabetes, and cardiovascular illnesses, by exploring genetic predispositions and novel chemopreventive agents. His work focuses on improving therapeutic efficacy and reducing public health burdens through innovative, patient-focused strategies and translational immunotherapy research.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses chronic disease pathology and translational immunotherapy, which are critical to U.S. public health and national healthcare innovation.

2 Well-positioned to Advance the Endeavor Met

The petitioner's MD degree, publication record in top-tier journals, and high citation count demonstrate his capability to lead this research.

3 Balance of Interests Met

The petitioner's expertise in monoclonal antibody production and next-generation sequencing provides a benefit to the U.S. that outweighs the need for labor certification.

Why This Petition Was Approved

The petition was approved based on 175 citations, 5 peer-reviewed journal articles, and 6 conference abstracts in top-tier immunology and nuclear medicine journals. One article ranked in the top 10% most cited in Clinical Medicine for its year, and the case satisfied all three Dhanasar prongs through premium processing in 15 days.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Conference Presentations
Original Contributions
Government Alignment

Similar Cases

Research Scientist

Biotechnology · China

WeGreened EB-2 (NIW) approved
California 354 days 2025-04-03
The petitioner proposes to advance the identification of new therapeutic targets for cancer, autoimmune diseases, and chronic inflammatory conditions using high-throughput technologies like single-cell sequencing. Her work focuses on examining T cell behavior within tumor microenvironments and immune responses to vaccines and cancer treatments to develop cost-effective strategies for immune modulation.
View Case

Doctor

Healthcare · Syria

WeGreened EB-2 (NIW) approved
Ohio 603 days 2025-10-11
The petitioner proposes to continue advancing patient-centric healthcare and medical research in the United States. Their work focuses on clinical practices and public health strategies, specifically addressing COVID-19 vaccination awareness, artificial intelligence in clinical settings, cardiac electrophysiology, and therapeutic optimization for cancer treatments. The endeavor aims to improve patient outcomes and strengthen U.S. public health systems through evidence-based care.
View Case

Clinical Research Coordinator

Biotechnology · Pakistan

WeGreened EB-2 (NIW) approved
Michigan 47 days 2025-05-12
The petitioner proposes to advance disease prevention and treatment strategies, specifically focusing on inflammatory bowel disease, heart disease, autoimmune disorders, and novel infections. The work involves optimizing and synthesizing predictive, therapeutic, and diagnostic modalities to improve clinical outcomes for pressing health issues.
View Case

Research Scientist

Biotechnology · India

WeGreened EB-2 (NIW) approved
93 days 2023-03-03
The petitioner proposes to refine diagnostic and therapeutic strategies for complex and chronic diseases by integrating molecular profiling, cellular modeling, and translational biomedical analysis. His work leverages multi-omics data and advanced bioanalysis to deepen the mechanistic understanding of disease progression and treatment response. The endeavor aims to translate biological discoveries into actionable improvements in precision medicine and clinical outcomes.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Healthcare cases More cases from Turkey

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-04-17.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 15 days
Criteria Met 3 / 3
Evidence Types 5

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Turkey All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist